Gujarat Themis Biosyn Ltd reports indirect encumbrance of 47% shareholding via promoter pledge

What Gujarat Themis Biosyn announced

Gujarat Themis Biosyn Limited (the "Company"), listed on NSE as THEMISMED and on BSE as 506879, filed a revised disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 21 July 2026. The filing informs the exchanges that an indirect encumbrance has been created over a substantial portion of the Company’s share capital held by its promoter, Pharmaceutical Business Group (India) Limited (PBGIL). The encumbrance stems from a pledge and a non‑disposal undertaking executed by Vividhmargi Investments Private Limited (VIPL) in favour of CTL Trusteeship Limited, the debenture trustee for Kotak Credit Opportunities Fund Trust.

Details of the indirect encumbrance

The pledge agreement dated 28 June 2026 and the accompanying non‑disposal undertaking cover two distinct blocks of PBGIL shares:

• Pledge: 25,24,245 equity shares of PBGIL, representing 51% of PBGIL’s issued and paid‑up share capital.
• Non‑disposal undertaking: 21,57,855 equity shares of PBGIL, representing 47.98% of PBGIL’s issued and paid‑up share capital.

PBGIL itself holds 5,12,40,000 equity shares of Gujarat Themis Biosyn, which corresponds to 47.02% of the Company’s total equity. Consequently, the pledge and non‑disposal undertaking on PBGIL shares translate into an indirect encumbrance over the entire 5.12 crore shareholding of GTBL held by PBGIL. The encumbrance is recorded as an “indirect encumbrance” in the filing, with CTL Trusteeship Limited named as the beneficiary of the pledge.

Shareholding impact

Prior to the encumbrance, PBGIL’s 5.12 crore shares gave the promoter group a near‑half stake in Gujarat Themis Biosyn, providing significant voting power and influence over corporate decisions. The creation of the pledge does not alter the legal ownership of those shares, but it does restrict the promoter’s ability to sell or otherwise dispose of them without the consent of the debenture trustee. The non‑disposal undertaking explicitly bars any transfer of the pledged shares, reinforcing the security interest held by the lender.

Regulatory filing and timeline

The SEBI (SAST) Regulations require promoters to disclose any creation, release or invocation of encumbrances within seven working days of the event. The timeline for this transaction is as follows:

• 29 June 2026: Date of creation of the pledge and non‑disposal undertaking (indirect encumbrance).
• 3 July 2026: Initial reporting of the encumbrance to the stock exchanges (BSE and NSE).
• 16 July 2026: A subsequent filing indicated a release of encumbrance, but the revised disclosure on 21 July 2026 clarifies that the indirect encumbrance remains in place for the full 5.12 crore shares.
• 21 July 2026: Revised disclosure filed, confirming the details of the pledge, the parties involved, and the extent of the indirect encumbrance.

The filing complies with Regulation 31(1) (creation of encumbrance) and Regulation 31(2) (subsequent revisions or releases). The document is addressed to both the BSE Corporate Relationship Department and the NSE Listing Department, ensuring that market participants receive consistent information.

Key facts at a glance

Why this matters for investors

The indirect pledge does not change the number of shares owned by the promoter group, but it does impose a security interest over those shares. From an investor’s perspective, the key implications are:

• Voting rights: While the shares remain in the promoter’s name, any attempt to exercise voting rights may be subject to the trustee’s consent, potentially limiting the promoter’s influence in shareholder meetings.
• Liquidity constraints: The non‑disposal undertaking prevents the promoter from selling the pledged shares without explicit approval, reducing the risk of a sudden large‑scale sell‑down that could affect market perception.
• Credit exposure: The pledge is tied to a debenture trust deed, indicating that the promoter has raised financing against its stake. Any default on the underlying loan could trigger enforcement actions, which might lead to a transfer of the pledged shares to the trustee.
• Regulatory compliance: The timely filing demonstrates adherence to SEBI’s disclosure norms, providing transparency to the market and reducing regulatory risk.

Investors should monitor any future filings that indicate a release, invocation, or modification of the encumbrance, as such events could alter the effective control dynamics within the company.

Conclusion

Gujarat Themis Biosyn Ltd’s revised filing on 21 July 2026 confirms that an indirect pledge and non‑disposal undertaking now cover the promoter’s 47.02% stake in the company. The encumbrance, created on 29 June 2026 and held by CTL Trusteeship Limited on behalf of Kotak Credit Opportunities Fund Trust, restricts any disposal of the pledged shares. While the promoter retains legal ownership, the security interest may affect voting power and future share transactions. Investors should watch for any subsequent disclosures that modify the status of this encumbrance.